Trial Outcomes & Findings for Understanding Disparities in Quitting in African American and White Smokers (NCT NCT01836276)

NCT ID: NCT01836276

Last Updated: 2018-10-24

Results Overview

Defined as having no cigarettes for the previous 7 days at the Week 26 visit. The recommended cut-off of 15ng/ml for salivary cotinine will be used to differentiate smokers from non-smokers.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

449 participants

Primary outcome timeframe

Change from Baseline to Week 26

Results posted on

2018-10-24

Participant Flow

Participant milestones

Participant milestones
Measure
African American Smokers
African Americans smokers received 12 weeks of Varenicline and 6 smoking cessation counseling sessions. Varenicline: 1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines
White Smokers
White smokers received 12 weeks of Varenicline and 6 smoking cessation counseling sessions. Varenicline: 1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines
Overall Study
STARTED
224
225
Overall Study
Week 4
198
186
Overall Study
Week 12
183
165
Overall Study
COMPLETED
196
174
Overall Study
NOT COMPLETED
28
51

Reasons for withdrawal

Reasons for withdrawal
Measure
African American Smokers
African Americans smokers received 12 weeks of Varenicline and 6 smoking cessation counseling sessions. Varenicline: 1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines
White Smokers
White smokers received 12 weeks of Varenicline and 6 smoking cessation counseling sessions. Varenicline: 1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines
Overall Study
Lost to Follow-up
28
51

Baseline Characteristics

Understanding Disparities in Quitting in African American and White Smokers

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
African American
n=224 Participants
12 weeks of varenicline and 6 counseling sessions.
White
n=225 Participants
12 weeks of varenicline and 6 counseling sessions.
Total
n=449 Participants
Total of all reporting groups
Age, Continuous
42.4 years
STANDARD_DEVIATION 12 • n=5 Participants
40.5 years
STANDARD_DEVIATION 11.2 • n=7 Participants
41.4 years
STANDARD_DEVIATION 11.6 • n=5 Participants
Sex: Female, Male
Female
112 Participants
n=5 Participants
112 Participants
n=7 Participants
224 Participants
n=5 Participants
Sex: Female, Male
Male
112 Participants
n=5 Participants
113 Participants
n=7 Participants
225 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
224 Participants
n=5 Participants
0 Participants
n=7 Participants
224 Participants
n=5 Participants
Race (NIH/OMB)
White
0 Participants
n=5 Participants
225 Participants
n=7 Participants
225 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Cohabitation Status
Living alone
142 Participants
n=5 Participants
115 Participants
n=7 Participants
257 Participants
n=5 Participants
Cohabitation Status
Living with a partner
82 Participants
n=5 Participants
110 Participants
n=7 Participants
192 Participants
n=5 Participants
Employment Status
Employed full-time
77 Participants
n=5 Participants
142 Participants
n=7 Participants
219 Participants
n=5 Participants
Employment Status
Employed part-time
41 Participants
n=5 Participants
29 Participants
n=7 Participants
70 Participants
n=5 Participants
Employment Status
Not currently employed
75 Participants
n=5 Participants
28 Participants
n=7 Participants
103 Participants
n=5 Participants
Employment Status
Retired
11 Participants
n=5 Participants
5 Participants
n=7 Participants
16 Participants
n=5 Participants
Employment Status
Student/homemaker
20 Participants
n=5 Participants
21 Participants
n=7 Participants
41 Participants
n=5 Participants
Education level
Less than high school (HS) graduate
30 Participants
n=5 Participants
14 Participants
n=7 Participants
44 Participants
n=5 Participants
Education level
HS graduate or HS equivalent (GED)
64 Participants
n=5 Participants
44 Participants
n=7 Participants
108 Participants
n=5 Participants
Education level
Some college or tech school
90 Participants
n=5 Participants
116 Participants
n=7 Participants
206 Participants
n=5 Participants
Education level
College graduate or higher
40 Participants
n=5 Participants
51 Participants
n=7 Participants
91 Participants
n=5 Participants
Health insurance that pays for most medical care
No
107 Participants
n=5 Participants
102 Participants
n=7 Participants
209 Participants
n=5 Participants
Health insurance that pays for most medical care
Yes
117 Participants
n=5 Participants
123 Participants
n=7 Participants
240 Participants
n=5 Participants
Income
21,293 Dollars
STANDARD_DEVIATION 15,501 • n=5 Participants
35,806 Dollars
STANDARD_DEVIATION 21,035 • n=7 Participants
28,566 Dollars
STANDARD_DEVIATION 19,840 • n=5 Participants
Number of people living in house, including self
2.7 Cohabitants
STANDARD_DEVIATION 1.6 • n=5 Participants
3.0 Cohabitants
STANDARD_DEVIATION 1.8 • n=7 Participants
2.8 Cohabitants
STANDARD_DEVIATION 1.7 • n=5 Participants
Housing
Own a home
38 Participants
n=5 Participants
77 Participants
n=7 Participants
115 Participants
n=5 Participants
Housing
Rent or stay with others
186 Participants
n=5 Participants
148 Participants
n=7 Participants
334 Participants
n=5 Participants
Perceived Health
Good, fair, or poor
125 Participants
n=5 Participants
113 Participants
n=7 Participants
238 Participants
n=5 Participants
Perceived Health
Very good/excellent
99 Participants
n=5 Participants
112 Participants
n=7 Participants
211 Participants
n=5 Participants
Percent Federal Poverty Level
< or = 100%
115 Participants
n=5 Participants
43 Participants
n=7 Participants
158 Participants
n=5 Participants
Percent Federal Poverty Level
101%-200%
72 Participants
n=5 Participants
87 Participants
n=7 Participants
159 Participants
n=5 Participants
Percent Federal Poverty Level
201%-250%
15 Participants
n=5 Participants
25 Participants
n=7 Participants
40 Participants
n=5 Participants
Percent Federal Poverty Level
251%-300%
9 Participants
n=5 Participants
27 Participants
n=7 Participants
36 Participants
n=5 Participants
Percent Federal Poverty Level
301%-400%
13 Participants
n=5 Participants
43 Participants
n=7 Participants
56 Participants
n=5 Participants
Height in inches
66.8 inches
STANDARD_DEVIATION 3.7 • n=5 Participants
66.8 inches
STANDARD_DEVIATION 3.9 • n=7 Participants
66.8 inches
STANDARD_DEVIATION 3.8 • n=5 Participants
Weight in pounds
195.3 pounds
STANDARD_DEVIATION 51.2 • n=5 Participants
182.9 pounds
STANDARD_DEVIATION 44.1 • n=7 Participants
189.1 pounds
STANDARD_DEVIATION 48.1 • n=5 Participants
BMI
30.8 kg/m^2
STANDARD_DEVIATION 8.1 • n=5 Participants
28.9 kg/m^2
STANDARD_DEVIATION 7.1 • n=7 Participants
29.8 kg/m^2
STANDARD_DEVIATION 7.7 • n=5 Participants
Waist circumference in inches
37.6 inches
STANDARD_DEVIATION 6.7 • n=5 Participants
36.3 inches
STANDARD_DEVIATION 6.2 • n=7 Participants
37.0 inches
STANDARD_DEVIATION 6.4 • n=5 Participants
Cigarettes per day
12.5 Cigarettes
STANDARD_DEVIATION 5.7 • n=5 Participants
16.9 Cigarettes
STANDARD_DEVIATION 4.6 • n=7 Participants
14.7 Cigarettes
STANDARD_DEVIATION 5.7 • n=5 Participants
Age when you started smoking regularly
18.5 years
STANDARD_DEVIATION 6.5 • n=5 Participants
16.5 years
STANDARD_DEVIATION 4.8 • n=7 Participants
17.5 years
STANDARD_DEVIATION 5.8 • n=5 Participants
Menthol smoker
Non-menthol
31 Participants
n=5 Participants
166 Participants
n=7 Participants
197 Participants
n=5 Participants
Menthol smoker
Menthol
193 Participants
n=5 Participants
59 Participants
n=7 Participants
252 Participants
n=5 Participants
Longest quit attempt in months
24.8 months
STANDARD_DEVIATION 70.9 • n=5 Participants
25.3 months
STANDARD_DEVIATION 51.7 • n=7 Participants
25.0 months
STANDARD_DEVIATION 62.0 • n=5 Participants
Time to first cigarette
After 30 minutes
47 Participants
n=5 Participants
57 Participants
n=7 Participants
104 Participants
n=5 Participants
Time to first cigarette
Within 30 minutes
177 Participants
n=5 Participants
168 Participants
n=7 Participants
345 Participants
n=5 Participants
Number of your five best friends smoke
2.9 friends
STANDARD_DEVIATION 1.8 • n=5 Participants
2.7 friends
STANDARD_DEVIATION 1.7 • n=7 Participants
2.8 friends
STANDARD_DEVIATION 1.8 • n=5 Participants
Number of smokers in the home(not including self)
0.6 cohabitants
STANDARD_DEVIATION 1.0 • n=5 Participants
0.6 cohabitants
STANDARD_DEVIATION 0.8 • n=7 Participants
0.6 cohabitants
STANDARD_DEVIATION 0.9 • n=5 Participants
Partner smoking status
No partner/spouse
94 Participants
n=5 Participants
78 Participants
n=7 Participants
172 Participants
n=5 Participants
Partner smoking status
Partner/spouse is a non-smoker
68 Participants
n=5 Participants
69 Participants
n=7 Participants
137 Participants
n=5 Participants
Partner smoking status
Partner/spouse is a smoker
62 Participants
n=5 Participants
78 Participants
n=7 Participants
140 Participants
n=5 Participants
Withdrawal
5.3 units on a scale
STANDARD_DEVIATION 4.3 • n=5 Participants
5.2 units on a scale
STANDARD_DEVIATION 3.1 • n=7 Participants
5.3 units on a scale
STANDARD_DEVIATION 3.8 • n=5 Participants
Craving
14.1 units on a scale
STANDARD_DEVIATION 7.9 • n=5 Participants
15.3 units on a scale
STANDARD_DEVIATION 6.7 • n=7 Participants
14.7 units on a scale
STANDARD_DEVIATION 7.3 • n=5 Participants
Perceived stress
4.5 units on a scale
STANDARD_DEVIATION 2.7 • n=5 Participants
3.6 units on a scale
STANDARD_DEVIATION 2.3 • n=7 Participants
4.1 units on a scale
STANDARD_DEVIATION 2.6 • n=5 Participants
Depression
2.1 units on a scale
STANDARD_DEVIATION 3.4 • n=5 Participants
1.2 units on a scale
STANDARD_DEVIATION 1.8 • n=7 Participants
1.7 units on a scale
STANDARD_DEVIATION 2.7 • n=5 Participants
Anxiety
3.0 units on a scale
STANDARD_DEVIATION 3.6 • n=5 Participants
2.1 units on a scale
STANDARD_DEVIATION 2.7 • n=7 Participants
2.5 units on a scale
STANDARD_DEVIATION 3.2 • n=5 Participants
Financial strain
15.6 units on a scale
STANDARD_DEVIATION 4.3 • n=5 Participants
14.6 units on a scale
STANDARD_DEVIATION 4.1 • n=7 Participants
15.1 units on a scale
STANDARD_DEVIATION 4.2 • n=5 Participants
Perceived discrimination
number of situations encountered
2.7 units on a scale
STANDARD_DEVIATION 1.6 • n=5 Participants
2.6 units on a scale
STANDARD_DEVIATION 1.6 • n=7 Participants
2.7 units on a scale
STANDARD_DEVIATION 1.6 • n=5 Participants
Perceived discrimination
frequency encountered
6.8 units on a scale
STANDARD_DEVIATION 5.1 • n=5 Participants
5.1 units on a scale
STANDARD_DEVIATION 4.1 • n=7 Participants
5.9 units on a scale
STANDARD_DEVIATION 4.9 • n=5 Participants
Race Consciousness
Never
109 Participants
n=5 Participants
158 Participants
n=7 Participants
267 Participants
n=5 Participants
Race Consciousness
Once a year
25 Participants
n=5 Participants
25 Participants
n=7 Participants
50 Participants
n=5 Participants
Race Consciousness
Once a month
22 Participants
n=5 Participants
18 Participants
n=7 Participants
40 Participants
n=5 Participants
Race Consciousness
Once a week
14 Participants
n=5 Participants
17 Participants
n=7 Participants
31 Participants
n=5 Participants
Race Consciousness
At least daily
54 Participants
n=5 Participants
7 Participants
n=7 Participants
61 Participants
n=5 Participants
Perceived social status
4.8 units on a scale
STANDARD_DEVIATION 1.5 • n=5 Participants
5.0 units on a scale
STANDARD_DEVIATION 1.5 • n=7 Participants
4.9 units on a scale
STANDARD_DEVIATION 1.5 • n=5 Participants
Satisfaction with life
20.1 units on a scale
STANDARD_DEVIATION 6.3 • n=5 Participants
23.8 units on a scale
STANDARD_DEVIATION 5.5 • n=7 Participants
22.0 units on a scale
STANDARD_DEVIATION 6.2 • n=5 Participants
Cynicism/distrust of others' intentions
5.7 units on a scale
STANDARD_DEVIATION 1.6 • n=5 Participants
4.8 units on a scale
STANDARD_DEVIATION 1.7 • n=7 Participants
5.3 units on a scale
STANDARD_DEVIATION 1.7 • n=5 Participants
Neuroticism/proneness to psychological stress
12.6 units on a scale
STANDARD_DEVIATION 7.1 • n=5 Participants
12.5 units on a scale
STANDARD_DEVIATION 6.3 • n=7 Participants
12.5 units on a scale
STANDARD_DEVIATION 6.7 • n=5 Participants
Social cohesion and trust
16.2 units on a scale
STANDARD_DEVIATION 4.7 • n=5 Participants
17.8 units on a scale
STANDARD_DEVIATION 4.5 • n=7 Participants
17.0 units on a scale
STANDARD_DEVIATION 4.7 • n=5 Participants
Neighborhood problems
15.5 units on a scale
STANDARD_DEVIATION 4.7 • n=5 Participants
13.5 units on a scale
STANDARD_DEVIATION 3.4 • n=7 Participants
14.5 units on a scale
STANDARD_DEVIATION 4.2 • n=5 Participants

PRIMARY outcome

Timeframe: Change from Baseline to Week 26

Defined as having no cigarettes for the previous 7 days at the Week 26 visit. The recommended cut-off of 15ng/ml for salivary cotinine will be used to differentiate smokers from non-smokers.

Outcome measures

Outcome measures
Measure
African American (AA) Smokers
n=224 Participants
AA smokers received 12 weeks of Varenicline and 6 smoking cessation counseling sessions. Varenicline: 1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines
White Smokers
n=225 Participants
White smokers received 12 weeks of Varenicline and 6 smoking cessation counseling sessions. Varenicline: 1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines
Number of Participants With Cotinine-verified 7-day Point Prevalence Smoking Abstinence at Week 26
32 Participants
55 Participants

Adverse Events

African American

Serious events: 1 serious events
Other events: 210 other events
Deaths: 0 deaths

White

Serious events: 5 serious events
Other events: 206 other events
Deaths: 1 deaths

Serious adverse events

Serious adverse events
Measure
African American
n=224 participants at risk
Varenicline treatment began at Week 0 and continued through Week 12. Adverse events were monitored through week 16.
White
n=225 participants at risk
Varenicline treatment began at Week 0 and continued through Week 12. Adverse events were monitored through week 16.
Cardiac disorders
Fluid on the heart
0.45%
1/224 • Number of events 1 • Adverse events were collected between weeks 0-16.
0.00%
0/225 • Adverse events were collected between weeks 0-16.
Psychiatric disorders
Depressive episode
0.00%
0/224 • Adverse events were collected between weeks 0-16.
0.44%
1/225 • Number of events 1 • Adverse events were collected between weeks 0-16.
Vascular disorders
Seizure
0.00%
0/224 • Adverse events were collected between weeks 0-16.
0.44%
1/225 • Number of events 1 • Adverse events were collected between weeks 0-16.
Cardiac disorders
Heart attack
0.00%
0/224 • Adverse events were collected between weeks 0-16.
0.44%
1/225 • Number of events 1 • Adverse events were collected between weeks 0-16.
Psychiatric disorders
Suicide attempt
0.00%
0/224 • Adverse events were collected between weeks 0-16.
0.44%
1/225 • Number of events 1 • Adverse events were collected between weeks 0-16.
Gastrointestinal disorders
Intestinal blockage
0.00%
0/224 • Adverse events were collected between weeks 0-16.
0.44%
1/225 • Number of events 1 • Adverse events were collected between weeks 0-16.

Other adverse events

Other adverse events
Measure
African American
n=224 participants at risk
Varenicline treatment began at Week 0 and continued through Week 12. Adverse events were monitored through week 16.
White
n=225 participants at risk
Varenicline treatment began at Week 0 and continued through Week 12. Adverse events were monitored through week 16.
Psychiatric disorders
Hostility, aggression, or other change in behavior not normal for you
5.9%
13/220 • Number of events 13 • Adverse events were collected between weeks 0-16.
6.1%
13/214 • Number of events 13 • Adverse events were collected between weeks 0-16.
General disorders
Fatigue or loss of energy
8.2%
18/220 • Number of events 18 • Adverse events were collected between weeks 0-16.
9.8%
21/214 • Number of events 21 • Adverse events were collected between weeks 0-16.
Gastrointestinal disorders
Nausea
15.5%
34/220 • Number of events 34 • Adverse events were collected between weeks 0-16.
20.1%
43/214 • Number of events 43 • Adverse events were collected between weeks 0-16.
General disorders
Trouble Sleeping
11.8%
26/220 • Number of events 26 • Adverse events were collected between weeks 0-16.
13.1%
28/214 • Number of events 28 • Adverse events were collected between weeks 0-16.
General disorders
Headaches
9.1%
20/220 • Number of events 20 • Adverse events were collected between weeks 0-16.
7.9%
17/214 • Number of events 17 • Adverse events were collected between weeks 0-16.
General disorders
Abnormal dreams
13.2%
29/220 • Number of events 29 • Adverse events were collected between weeks 0-16.
4.2%
9/214 • Number of events 9 • Adverse events were collected between weeks 0-16.
Gastrointestinal disorders
Gas or flatulence
16.8%
37/220 • Number of events 37 • Adverse events were collected between weeks 0-16.
15.0%
32/214 • Number of events 32 • Adverse events were collected between weeks 0-16.
Gastrointestinal disorders
Constipation
11.8%
26/220 • Number of events 26 • Adverse events were collected between weeks 0-16.
8.4%
18/214 • Number of events 18 • Adverse events were collected between weeks 0-16.
General disorders
Dizziness
3.6%
8/220 • Number of events 8 • Adverse events were collected between weeks 0-16.
1.4%
3/214 • Number of events 3 • Adverse events were collected between weeks 0-16.
General disorders
Dry mouth
8.2%
18/220 • Number of events 18 • Adverse events were collected between weeks 0-16.
7.9%
17/214 • Number of events 17 • Adverse events were collected between weeks 0-16.
Psychiatric disorders
Irritability
10.9%
24/220 • Number of events 24 • Adverse events were collected between weeks 0-16.
12.6%
27/214 • Number of events 27 • Adverse events were collected between weeks 0-16.

Additional Information

Dr. Nicole Nollen

University of Kansas Medical Center

Phone: 913-588-3784

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place